Drug intelligence / Profile preview

temozolomide + lomustine + vincristine

Development stage: Unknown
Lead developer: Finnish Melanoma Group
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

TOL is an investigational **combination chemotherapy regimen** comprising temozolomide, lomustine, and vincristine. Temozolomide and lomustine are DNA-alkylating cytotoxic agents, while vincristine disrupts mitotic microtubule formation. The Finnish Melanoma Group evaluated TOL with subcutaneous interferon-alpha, with or without vemurafenib, in the completed COBRA study for previously untreated unresectable advanced melanoma; interferon-alpha and vemurafenib are not components of TOL itself. ([tandfonline.com](https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2019.1670862))

Other names: temozolomide + lomustine + vincristineTOL

Targets

DNATOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on temozolomide + lomustine + vincristine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on temozolomide + lomustine + vincristine.

Explore the full profile